Irina Katz, | |
11504 Piney Lodge Rd, North Potomac, MD 20878-2444 | |
(202) 854-9812 | |
Not Available |
Full Name | Irina Katz |
---|---|
Gender | Female |
Speciality | Counselor |
Location | 11504 Piney Lodge Rd, North Potomac, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154814705 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 149020587 (Illinois) | Secondary |
101Y00000X | Counselor | LC50081682 (District Of Columbia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Irina Katz, 11504 Piney Lodge Rd, North Potomac, MD 20878 Ph: (202) 854-9812 | Irina Katz, 11504 Piney Lodge Rd, North Potomac, MD 20878-2444 Ph: (202) 854-9812 |
News Archive
Black people who are married don't appear to live any longer than black couples who simply live together, suggesting marriage doesn't boost longevity for blacks the way it does for whites, according to a large national study led by Michigan State University.
Vical Incorporated today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $2.25 per share. The gross proceeds to us from this offering are expected to be approximately $33.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering is expected to close on or about September 29, 2010, subject to customary closing conditions.
As the restaurant industry prepares to implement new rules requiring chains with 20 or more locations to post calorie content information, the results of a new study suggest that it would be beneficial to public health for all restaurants to provide consumers with the nutritional content of their products.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
› Verified 7 days ago